Health Canada Approves Eli Lilly's Daily Oral GLP-1 Pill Foundayo for Weight Loss and Type 2 Diabetes
Health Canada has authorized Foundayo, a daily oral GLP-1 medication by Eli Lilly, for weight loss and Type 2 diabetes treatment in adults. The drug is expected to reach Canadian pharmacies in January.
Health Canada authorized Foundayo, a new daily oral GLP-1 pill developed by Eli Lilly, on November 13. The medication is approved for weight loss in adults with obesity, as well as those who are overweight with at least one related medical problem such as high blood pressure or sleep apnea. In addition to weight management, Foundayo is approved to help treat Type 2 diabetes.

The active ingredient in Foundayo is orforglipron, a non-peptide GLP-1 receptor agonist. Because orforglipron is a smaller molecule than peptide-based drugs like semaglutide and tirzepatide, it can be taken orally and absorbed without being broken down by the digestive system. This provides a daily oral alternative to the weekly injections currently used for weight loss and Type 2 diabetes treatment.
Eli Lilly spokesperson Ethan Pigott stated that the company expects Foundayo pills to be available in Canadian pharmacies in January. Common side effects of GLP-1 medications, including Foundayo, involve gastrointestinal issues such as nausea or vomiting.
Dr. Ehud Ur noted that while Foundayo seems comparable or better for weight loss than semaglutide and tirzepatide, he is waiting for clinical trial results regarding its cardiovascular benefits before prescribing it.

Foundayo's entry introduces competition in the Canadian GLP-1 weight-loss market alongside existing injectables. Novo Nordisk's Rybelsus is already on the market in Canada but is only approved for Type 2 diabetes management, not for weight loss. Meanwhile, Novo Nordisk's oral Wegovy pill is currently awaiting Health Canada approval, though it is already approved and available in the United States.